BioSpace News Archive

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and thirty thousand by issuing thirteen million ordinary shares.

PacBio announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units covering 39,800 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan, effective on March 18, 2024.

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended December 31, 2023 financial results.

NLS Pharmaceutics Ltd. announced the closing of its previously announced registered direct offering of 7,000,000 of its common shares at a purchase price of $0.25 per share.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

NurExone Biologic Inc., a pioneering biopharmaceutical company, developing regenerative medicine therapies, is proud to announce a strategic service agreement with Vivox Ltd., a leading provider of animal testing and services in Israel to biotech and pharmaceutical companies.

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) announces the appointment of Tyler Burpee to the board of directors and the resignation of director Ian Kim for personal reasons, effective March 21st, 2024.

In response to the recent safety communications issued by the U.S. Food and Drug Administration regarding concerns over plastic syringes and safety needles manufactured in China, HTL-Strefa Inc.

Iovance Biotherapeutics, Inc. announced that on March 22, 2024, the Company approved the grant of inducement stock options covering an aggregate of 97,700 shares of Iovance’s common stock to twenty new, non-executive employees.

Biophytis SA presented its phase 3 protocol aimed at demonstrating the potential of RuvembriTM in the treatment of sarcopenia at the International Conference on Frailty and Sarcopenia Research, held from March 20 to 22, 2024 in Albuquerque, NM, USA.